Schedule 13G ownership disclosure
Aclaris Therapeutics Inc
Common Stock, par value $0.00001 per share · CUSIP: 00461U105
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Adage Capital Management, L.P.
Shares: 8,201,344.00 · Class: 7.60%
- Robert Atchinson
Shares: 8,201,344.00 · Class: 7.60%
- Phillip Gross
Shares: 8,201,344.00 · Class: 7.60%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-002248
- Form type
- SCHEDULE 13G/A
- Filer
- Aclaris Therapeutics, Inc.
- CIK
- CIK 1557746
- Filed
- May 12, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership